Eleven P15

Next Generation Diagnostics and Treatment for Pulmonary Fibrosis



Genetics and Biomarkers


Eleven P15 focuses on the development of biomarkers that enable early detection of idiopathic pulmonary fibrosis, and the discovery of genetically-targeted therapeutic approaches to treat and prevent this incurable disease.



Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and localized to the lung. IPF is a fatal disease with median survival at 3-5 years. Two drugs have been approved for treatment of IPF, but these drugs fail to reverse scarred lung tissue or to improve survival. Accurate diagnosis of IPF is challenging. In a national IPF survey, 42% endured a year or more between first experienced symptoms and diagnosis; 55% were misdiagnosed at least once.


Eleven P15


Scientific Team

IPF Genetics: David Schwartz, MD

Mucus Biology: Chris Evans, PhD

Biomarkers: Ivana Yang, PhD

Genetics: Tasha Fingerlin, PhD

Chief Officers

CEO: Bruce Schroffel, MS/MPH

CSO: David Schwartz, MD

Contact Us


Eleven P15